Exelixis (EXEL) Stock Price
Exelixis Price
Exelixis (EXEL) Stock | ISIN US30161Q1040 | WKN 936718. The current Exelixis stock price is 51.74 USD (2026). Revenue is 2.64 B USD. Net income is 884.23 M USD. The P/E ratio is 16.49. Market capitalization is 14.58 B USD. Exelixis operates in the Health sector.
Exelixis stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Exelixis over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Exelixis stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Exelixis's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Exelixis Price |
|---|
Exelixis Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Exelixis Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Exelixis generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Exelixis retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Exelixis's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Exelixis has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Exelixis's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Exelixis stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Exelixis Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Exelixis business model & stock analysis
Exelixis SWOT Analysis
Strengths
1. Strong product portfolio: Exelixis Inc offers a diverse range of innovative pharmaceutical products, giving the company a competitive edge in the market.
2. Robust research and development (R&D) capabilities: The company has invested heavily in R&D, allowing them to continuously develop new and improved drugs.
3. Established reputation: Exelixis Inc has built a solid reputation for delivering high-quality products and has gained the trust of healthcare professionals worldwide.
Weaknesses
1. Reliance on key products: The company's revenue heavily relies on a few key products, which could pose a risk if sales decline or face regulatory issues.
2. Limited geographic presence: Exelixis Inc primarily operates in select markets, limiting its potential customer base and growth opportunities.
3. Vulnerability to market competition: Intense competition from rival pharmaceutical companies could impact market share and profitability.
Opportunities
1. Expansion into new markets: Exelixis Inc can explore untapped markets or enter into strategic partnerships to reach a wider customer base.
2. Growing demand for innovative therapies: With rising healthcare needs and advancements in medical science, there is an increasing demand for new and effective treatments.
3. Emerging markets: The company can take advantage of opportunities offered by emerging markets, where healthcare infrastructure and access to medicines are improving.
Threats
1. Stringent regulatory environment: Regulatory changes or delays in obtaining approvals may impact the company's ability to launch new products or expand into new markets.
2. Intellectual property challenges: Exelixis Inc may face patent infringements or challenges, potentially affecting the exclusivity and profitability of its products.
3. Economic uncertainties: Global economic fluctuations, healthcare reforms, or changes in insurance coverage could impact consumer spending on pharmaceuticals.
Exelixis Segments
Exelixis Revenue by Segment (1/8)
Max
Details
Exelixis Revenue by Segment (2/8)
Max
Details
Exelixis Revenue by Segment (3/8)
3 Years
5 Years
10 Years
25 Years
Max
Details
Exelixis Revenue by Segment (4/8)
3 Years
5 Years
10 Years
25 Years
Max
Details
Exelixis Revenue by Segment (5/8)
Max
Details
Exelixis Revenue by Segment (6/8)
3 Years
5 Years
10 Years
25 Years
Max
Details
Exelixis Revenue by Segment (7/8)
3 Years
5 Years
10 Years
25 Years
Max
Details
Exelixis Revenue by Segment (8/8)
Max
Details
Exelixis Revenue by Region
3 Years
5 Years
Max
Details
Exelixis Eulerpool Fair Value
Exelixis historical P/E ratio, EBIT multiple, and P/S ratio
Exelixis annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Exelixis shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Exelixis Earnings Estimates
Exelixis Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/6/2026 | 0.74USD | 617.42 MUSD | 2026 Q1 |
| 2/10/2026 | 0.78USD | 616.02 MUSD | 2025 Q4 |
| 1/12/2026 | 0.71USD | 621.61 MUSD | 2025 Q4 |
| 4/30/2024 | 0.2USD | 493.85 MUSD | 2024 Q1 |
| 2/5/2024 | 0.23USD | 499.47 MUSD | 2023 Q4 |
| 8/1/2023 | 0.24USD | 450.16 MUSD | 2023 Q2 |
| 5/2/2023 | 0.24USD | 433.57 MUSD | 2023 Q1 |
| 2/15/2023 | 0.26USD | 476.39 MUSD | 2023 Q4 |
| 11/1/2022 | 0.19USD | 409.1 MUSD | 2022 Q3 |
| 8/9/2022 | 0.19USD | 396.78 MUSD | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Exelixis stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Exelixis shareholder structure
| % | Name |
|---|---|
9.12316% | |
9.02174% | |
5.57345% | |
4.93646% | |
4.84575% | |
3.72214% | |
2.82438% | |
2.74812% | |
2.67121% | |
1.87228% |
Exelixis Executives and Management Board
Dr. Michael Morrissey
(64)President, Chief Executive Officer, Director · since 2000
Mr. Christopher Senner
(57)Chief Financial Officer, Executive Vice President
Mr. Patrick Haley
(49)Executive Vice President - Commercial
Mr. Jeffrey Hessekiel
(56)Executive Vice President
Dr. Dana Aftab
(62)Executive Vice President - Research and Development
Frequently asked questions about Exelixis
The business model of Exelixis Inc is focused on the development, commercialization, and discovery of therapies for the treatment of cancer. The company primarily engages in the research and development of small molecule therapies, targeting specific pathways that contribute to the growth and spread of cancer cells. Exelixis Inc aims to bring innovative and effective cancer treatments to patients by leveraging its expertise in drug discovery and development. The company collaborates with various partners, including pharmaceutical companies and research institutions, to advance its pipeline of potential oncology treatments.
Exelixis stock
Exelixis Peer Group
Exelixis Ticker
Exelixis FIGI
All fundamentals and in-depth analysis of Exelixis
Our stock analysis for Exelixis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Exelixis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.